Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia have?
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia has 399 citations in the OpenAlex counts ScholarIQ stores.
When was Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia published?
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia has 2008 year in the ScholarIQ index.
What is the open-access status of Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia?
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia has bronze oa status in the ScholarIQ index.
What is the DOI of Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia?
The DOI for Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia is on the source record.
What is the PMID of Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia?
The PMID for Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia is on the source record.
What is the OpenAlex record for Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia?
The OpenAlex for Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia is on the source record.